Senate Eyes CLIA Reform; House Floats Alternative LDT Plan; Industry Split

The Senate health committee is soliciting feedback from key stakeholders on how to modernize the Clinical Laboratory Improvement Amendments (CLIA) as a solution for government oversight of laboratory-developed tests, while House Energy & Commerce lawmakers simultaneously reach out to stakeholders on an alternative legislative proposal that would set up a new FDA center responsible for in vitro tests. Industry groups remain split on how to tackle the issue, with the American Clinical Laboratory Association (ACLA) continuing to favor a CMS-led...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.